Developer docs
API playgroundTry for free, no card

Search company profiles

Colospan

Full company profile

uuid0002nvv

Namestring
Colospan
Legal namestring
Colospan Ltd.
Websiteurl
colospan.com
Company typeenum
Private
Founded yearint
2009
Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
intraluminal bypass devices, colorectal surgical devices, anastomosis protection, medical device manufacturing, colorectal surgery solutions
Industry1 code
PRIMARYHLAHADAB
Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Colorectal Surgery Medical Devices
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Colospan generates revenue through the sale of its CG-100 intraluminal bypass device. The device is currently commercially available in the European Union and Israel, with plans to expand commercialization to Germany, Austria, and Switzerland in H2 2026.

colospan.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Pricing details1 tier
1Device pricing for hospitals and surgical centers
ModelOtherBilling cadenceOther
Notes

Pricing not publicly disclosed. Economic analysis demonstrates potential savings of up to $40,000 per patient by eliminating stoma supplies and reversal surgery costs.

colospan.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Colospan develops, manufactures, and commercializes the CG-100 intraluminal bypass device, a CE-marked soft silicone device placed through the anus during colorectal surgery to protect the anastomosis site. The device uses inflatable balloons and a securing ring for in-place retention and is removed non-surgically after 10 days as an alternative to diverting stoma. It is sold to hospitals and surgical centers across the EU and Israel, with U.S. availability through an active FDA IDE pivotal trial.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Up to 20% of colorectal surgery patients experience anastomotic leaks; CG-100 clinical data shows 3% leak rate
+3 more records
Product overview1 text field

Colospan is a commercial-stage medical device company with a single flagship product: the CG-100 intraluminal bypass device. The CG-100 is a CE-marked (under EU MDR) and Israel-approved device designed as an alternative to diverting stomas in colorectal surgery. It is made of soft silicone, deployed during primary surgery through the anus, uses inflatable balloons and a securing ring to protect the surgical anastomosis site, and is removed non-surgically after 10 days. The company is currently conducting a pivotal clinical study under FDA Investigational Device Exemption (IDE) with FDA Breakthrough Device Designation for the U.S. market.

Product and service1 record
1CG-100 Intraluminal Bypass Device
CategoryColorectal Surgery Medical Device
Description

The CG-100 is a CE-marked (under EU MDR) intraluminal bypass device made of soft silicone that is placed through the anus during colorectal surgery to protect the surgical anastomosis. It uses inflatable balloons and a securing ring to stay in place and is removed non-surgically after 10 days as an alternative to diverting stoma, intended for hospitals and surgical centers performing colorectal cancer resections.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeOthersAnnounced on2026-06-08
Description

Galmed Pharmaceuticals acquired Colospan Ltd. in a $4.5 million deal ($2.5 million cash plus $2.0 million in Galmed ordinary shares, with restructured terms adding $800,000 cash and replacing $2.0 million share payment with earnout capped at $2.0 million from Q3 2027). The acquisition creates a GI-focused medtech platform targeting the $6 billion gastrointestinal market addressing anastomotic leak complications in colorectal surgery.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-09
Description

Asklepios Altona Clinic in Hamburg became the first hospital in Germany to use the novel CG-100 intraluminal device in patients undergoing colorectal surgery, marking a key European clinical adoption partnership.

3Clalit HMO
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-08-16
Description

Clalit HMO, a major Israeli health maintenance organization, executed a purchasing code for the CG-100 intraluminal bypass device, representing a significant commercial distribution partnership in the Israeli market.

colospan.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Henry Ford Hospital in Detroit was the first in the United States to perform an investigational procedure with the CG-100 intraluminal device in patients undergoing colorectal anastomosis as part of the FDA IDE clinical trial.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Ethicon is the largest manufacturer of surgical staplers and anastomosis products used in colorectal surgery. Its portfolio competes for share of the same procedure budget that CG-100 targets, and any new anastomotic protection device must be benchmarked against Ethicon's installed stapling systems.

TypeBroad incumbent
Description

Medtronic (via the former Covidien) is a major supplier of surgical staplers, GI stents, and colorectal surgery devices. Its broad GI and surgical portfolios overlap with the clinical workflow in which CG-100 is deployed.

3Cook Medical
TypeDirect peer
Description

Cook Medical manufactures GI and colorectal devices including stents and intraluminal products. Its focus on GI intervention makes it the most directly comparable medtech peer in terms of clinical call point and product type.

TypeBroad incumbent
Description

Boston Scientific has a substantial GI and endoscopy portfolio including intraluminal devices and stents. It serves the same gastroenterology and colorectal surgery customers and competes for procedural budgets.

TypeDirect peer
Description

Applied Medical produces surgical access and colorectal surgery devices used in the same operating room procedures as CG-100. Its portfolio includes access systems and wound protection products that intersect with the colorectal surgery workflow.

TypeEmerging player
Description

Intuitive Surgical's da Vinci platform is widely used for robotic colorectal resection, the procedure in which CG-100 is deployed. While not a direct device competitor, it shapes the surgical workflow and adoption dynamics for adjunct devices like CG-100.

TypeBroad incumbent
Description

Olympus is a leading manufacturer of GI endoscopes and related therapeutic accessories. Its installed base defines the GI procedural environment in which CG-100 must integrate and gain surgeon acceptance.

TypeBroad incumbent
Description

BD manufactures surgical instruments and a growing portfolio of GI and colorectal intervention products. Its scale and hospital relationships make it a relevant incumbent peer for any surgical GI device commercialization.

TypeBroad incumbent
Description

B. Braun supplies surgical instruments, GI devices, and colorectal surgery products globally. Its broad surgical portfolio and European footprint make it a relevant comparable for CG-100's planned EU commercialization.

TypeEmerging player
Description

Conmed is a smaller medtech company focused on surgical and GI devices. Its narrower portfolio and overlap with colorectal procedural products make it a useful emerging-player comparable for Colospan's scale and stage.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Colospan

Colorectal Surgery Medical Devicescolospan.com

Colospan firmographics

Firmographics
Name
Colospan
Legal name
Colospan Ltd.
Website
https://colospan.com
Company type
Private
Founded year
2009
Operating status
Acquired
Headcount range
1–10 employees
Ownership category
akta.pro rank

Colospan industry classification

Industry
Product category
Colorectal Surgery Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHADAB
Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment

Keywords

  • Intraluminal bypass devices
  • Colorectal surgical devices
  • Anastomosis protection
  • Medical device manufacturing
  • Colorectal surgery solutions

Where Colospan is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Colospan business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Medical Device Sales: Colospan generates revenue through the sale of its CG-100 intraluminal bypass device. The device is currently commercially available in the European Union and Israel, with plans to expand commercialization to Germany, Austria, and Switzerland in H2 2026.

Pricing tiers

ModelBillingPrice
OtherOtherDevice pricing for hospitals and surgical centers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Colospan product offering

Product offering

Core offering

Colospan develops, manufactures, and commercializes the CG-100 intraluminal bypass device, a CE-marked soft silicone device placed through the anus during colorectal surgery to protect the anastomosis site. The device uses inflatable balloons and a securing ring for in-place retention and is removed non-surgically after 10 days as an alternative to diverting stoma. It is sold to hospitals and surgical centers across the EU and Israel, with U.S. availability through an active FDA IDE pivotal trial.

Product overview

Colospan is a commercial-stage medical device company with a single flagship product: the CG-100 intraluminal bypass device. The CG-100 is a CE-marked (under EU MDR) and Israel-approved device designed as an alternative to diverting stomas in colorectal surgery. It is made of soft silicone, deployed during primary surgery through the anus, uses inflatable balloons and a securing ring to protect the surgical anastomosis site, and is removed non-surgically after 10 days. The company is currently conducting a pivotal clinical study under FDA Investigational Device Exemption (IDE) with FDA Breakthrough Device Designation for the U.S. market.

Differentiator

Problem solved

Functional benefit

Products and services

  • CG-100 Intraluminal Bypass Device The CG-100 is a CE-marked (under EU MDR) intraluminal bypass device made of soft silicone that is placed through the anus during colorectal surgery to protect the surgical anastomosis. It uses inflatable balloons and a securing ring to stay in place and is removed non-surgically after 10 days as an alternative to diverting stoma, intended for hospitals and surgical centers performing colorectal cancer resections.

Quantifiable outcome

  • Up to 20% of colorectal surgery patients experience anastomotic leaks; CG-100 clinical data shows 3% leak rate
  • +3 more outcomes

Companies that use Colospan

Customer profile

Named customers3 records

Segments1 record

Ideal customer profiles1 record

Colospan technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Colospan partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and major.

  • Galmed PharmaceuticalscoreOthers · 8 June 2026Galmed Pharmaceuticals acquired Colospan Ltd. in a $4.5 million deal ($2.5 million cash plus $2.0 million in Galmed ordinary shares, with restructured terms adding $800,000 cash and replacing $2.0 million share payment with earnout capped at $2.0 million from Q3 2027). The acquisition creates a GI-focused medtech platform targeting the $6 billion gastrointestinal market addressing anastomotic leak complications in colorectal surgery.
  • Asklepios Altona CliniccoreStrategic or Co-development Partner · 9 October 2024Asklepios Altona Clinic in Hamburg became the first hospital in Germany to use the novel CG-100 intraluminal device in patients undergoing colorectal surgery, marking a key European clinical adoption partnership.
  • Clalit HMOmajorChannel Partner/ Reseller/ Distributor · 16 August 2021Clalit HMO, a major Israeli health maintenance organization, executed a purchasing code for the CG-100 intraluminal bypass device, representing a significant commercial distribution partnership in the Israeli market.
  • Henry Ford HospitalcoreStrategic or Co-development PartnerHenry Ford Hospital in Detroit was the first in the United States to perform an investigational procedure with the CG-100 intraluminal device in patients undergoing colorectal anastomosis as part of the FDA IDE clinical trial.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Colospan competitors and assessment

Company assessment

Broad incumbents

  • Ethicon (Johnson & Johnson): Ethicon is the largest manufacturer of surgical staplers and anastomosis products used in colorectal surgery. Its portfolio competes for share of the same procedure budget that CG-100 targets, and any new anastomotic protection device must be benchmarked against Ethicon's installed stapling systems.
  • Medtronic: Medtronic (via the former Covidien) is a major supplier of surgical staplers, GI stents, and colorectal surgery devices. Its broad GI and surgical portfolios overlap with the clinical workflow in which CG-100 is deployed.
  • Boston Scientific: Boston Scientific has a substantial GI and endoscopy portfolio including intraluminal devices and stents. It serves the same gastroenterology and colorectal surgery customers and competes for procedural budgets.
  • Olympus Corporation: Olympus is a leading manufacturer of GI endoscopes and related therapeutic accessories. Its installed base defines the GI procedural environment in which CG-100 must integrate and gain surgeon acceptance.
  • Becton Dickinson (BD): BD manufactures surgical instruments and a growing portfolio of GI and colorectal intervention products. Its scale and hospital relationships make it a relevant incumbent peer for any surgical GI device commercialization.
  • B. Braun Melsungen: B. Braun supplies surgical instruments, GI devices, and colorectal surgery products globally. Its broad surgical portfolio and European footprint make it a relevant comparable for CG-100's planned EU commercialization.

Direct peers

  • Cook Medical: Cook Medical manufactures GI and colorectal devices including stents and intraluminal products. Its focus on GI intervention makes it the most directly comparable medtech peer in terms of clinical call point and product type.
  • Applied Medical Resources: Applied Medical produces surgical access and colorectal surgery devices used in the same operating room procedures as CG-100. Its portfolio includes access systems and wound protection products that intersect with the colorectal surgery workflow.

Emerging players

  • Intuitive Surgical: Intuitive Surgical's da Vinci platform is widely used for robotic colorectal resection, the procedure in which CG-100 is deployed. While not a direct device competitor, it shapes the surgical workflow and adoption dynamics for adjunct devices like CG-100.
  • Conmed Corporation: Conmed is a smaller medtech company focused on surgical and GI devices. Its narrower portfolio and overlap with colorectal procedural products make it a useful emerging-player comparable for Colospan's scale and stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Colospan social profiles

Digital presence

Colospan compliance and trust

Trust signal

Compliance3 records

Colospan financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Colospan leadership team

Management profile

Number of profiles

Profiles6 records

Colospan funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Colospan M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Colospan

What does Colospan do?

Colospan develops, manufactures, and commercializes the CG-100 intraluminal bypass device, a CE-marked soft silicone device placed through the anus during colorectal surgery to protect the anastomosis site. The device uses inflatable balloons and a securing ring for in-place retention and is removed non-surgically after 10 days as an alternative to diverting stoma. It is sold to hospitals and surgical centers across the EU and Israel, with U.S. availability through an active FDA IDE pivotal trial.

Is Colospan a public or private company?

Colospan is a private company. It is classified as corporate owned and is currently acquired.

When was Colospan founded?

Colospan was founded in 2009. It employs 1 to 10 people.

Where is Colospan based?

Colospan is headquartered in Cambridge, United States, in the North America region.

How does Colospan make money?

One revenue line is on record: medical Device Sales.

Who are Colospan's main competitors?

Broad incumbents on record are Ethicon (Johnson & Johnson), Medtronic, Boston Scientific, Olympus Corporation, Becton Dickinson (BD) and B. Braun Melsungen. Direct peers are Cook Medical and Applied Medical Resources. Emerging players are Intuitive Surgical and Conmed Corporation.

Does Colospan have an API?

No public API is recorded for Colospan.

What industry is Colospan in?

Colospan's product category is Colorectal Surgery Medical Devices. Its primary akta.pro industry code is HLAHADAB, Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical Device NetworkColospan signs European distribution agreement for CG-100 deviceColospan signed its first European commercial distribution agreement with Hospital Line for its CG-100 intraluminal bypass device, granting exclusive rights in Cyprus and Greece. The contract includes exclusivity terms and commercial targets, serving as a base for potential European expansion. The upcoming rollout will run alongside Colospan's pivotal study of the CG-100 in the US.Medical Device NetworkGalmed’s Colospan completes feasibility study of colon tissue platformGalmed Pharmaceuticals' subsidiary Colospan completed a feasibility study for an intraoperative platform to assess colon tissue quality, successfully measuring tissue compliance in 32 patients during colorectal cancer surgeries in Israel. The study confirmed technical feasibility without failures, supporting the development of a device to provide surgeons with quantitative data on tissue mechanical properties. Galmed plans to advance this technology toward future clinical trials and regulatory submissions based on these positive results.AijournGalmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan’s Novel Intraoperative Tissue Assessment TechnologyColospan Ltd., a subsidiary of Galmed Pharmaceuticals Ltd., successfully completed a feasibility study involving 32 colorectal cancer patients at three clinical centers in Israel, demonstrating the viability of a novel intraoperative tissue assessment technology. This technology aims to provide real-time, objective measurements of colon tissue quality during surgeries, potentially aiding in surgical decision-making and improving patient outcomes. The study reinforces Galmed's strategy to innovate in GI oncology and colorectal surgery, expanding Colospan's product pipeline.Investing.comGalmed completes feasibility study for colon tissue assessment tech By Investing.comGalmed Pharmaceuticals completed a feasibility study for a colon tissue assessment platform through its subsidiary Colospan Ltd., demonstrating that quantitative measurement of colon tissue compliance is feasible in 32 colorectal cancer patients. The technology aims to provide surgeons with real-time data on tissue mechanical properties to support intraoperative decision-making during colorectal surgery. This development complements Colospan's existing CG-100 device, which has received FDA Breakthrough Device Designation.Investing.comGalmed completes acquisition of medical device firm Colospan By Investing.comGalmed Pharmaceuticals Ltd. announced the completion of its acquisition of Colospan Ltd., a commercial-stage medical device company specializing in colorectal surgery complications, following a restructuring of the original deal terms. Under the revised agreement, Galmed increased the cash payment by $800,000 to reduce immediate shareholder dilution, replacing a planned $2.0 million share payment with an earnout structure capped at $2.0 million tied to net sales revenue performance beginning in Q3 2027. Colospan's flagship product, the CG-100 intraluminal bypass device, holds CE marking under the EU Medical Device Regulation and is approved in Israel, with clinical data from 97 patients showing a 3% anastomotic leak rate.Investing.comGalmed completes acquisition of medical device firm Colospan By Investing.comGalmed Pharmaceuticals Ltd. announced the completion of its acquisition of Colospan Ltd., a commercial-stage medical device company, following restructured deal terms that increased cash payment by $800,000 to reduce immediate shareholder dilution while replacing a $2.0 million share payment with an earnout capped at $2.0 million from Q3 2027. The deal, valued at $4.5 million ($2.5 million cash plus $2.0 million in Galmed ordinary shares), gives Galmed access to Colospan's CG-100 intraluminal bypass device, which holds CE marking in the EU and approval in Israel for protecting colorectal anastomoses, though it remains unapproved in the United States. The acquisition aligns with Galmed's gastrointestinal focus at a time when its stock has declined 69% over the past year, leaving it with a market capitalization of $3.82 million and a cash balance of $15.6 million.Investing.comGalmed completes acquisition of medical device firm Colospan By Investing.comGalmed Pharmaceuticals Ltd. announced it has completed the acquisition of Colospan Ltd., a commercial-stage medical device company, following restructuring of deal terms that increased the cash payment by $800,000 to reduce immediate shareholder dilution. The deal eliminates a planned $2.0 million share payment at closing, replacing it with an earnout capped at $2.0 million tied to net sales revenue performance beginning Q3 2027. Colospan's CG-100 intraluminal bypass device holds CE marking in the EU and Israeli approval but remains unapproved in the United States, with clinical data from 97 patients showing 90% avoided stoma creation.PR NewswireGalmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of AcquisitionGalmed Pharmaceuticals Ltd. has consummated the acquisition of Colospan Ltd., restructuring the financial terms to prioritize shareholder value protection by increasing the initial cash payment and replacing an immediate share issuance with a performance-based earnout. The acquisition provides Galmed with CG-100, a CE-marked medical device for colorectal surgery, enabling potential revenue generation in Europe and Israel while establishing a unified gastrointestinal platform combining biopharmaceutical and medtech capabilities. Clinical data supports the device's efficacy in avoiding stoma creation, with plans to submit real-world data to the FDA to support ongoing pivotal studies.Stock TitanGalmed closes Colospan acquisition, keeps cash outlayGalmed Pharmaceuticals announced the completion of its acquisition of Colospan Ltd., a commercial-stage medical device company, following a restructuring of the original terms to reduce shareholder dilution. Instead of the originally planned $2.0 million share issuance at closing, Galmed will pay an additional $800,000 in cash plus a sales-based earnout capped at $2.0 million commencing in Q3 2027. The acquisition gives Galmed access to Colospan's CG-100 intraluminal bypass device, which is CE marked in the EU and Israel, with FDA Breakthrough Device Designation, enabling potential near-term revenue generation in Europe.PharmExecPharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly BioIncyte announced its acquisition of Vega Therapeutics in a deal valued at approximately $2 billion, targeting a Phase III bleeding disorder antibody. Galmed Pharmaceuticals revealed plans to acquire Colospan, marking a strategic pivot into gastrointestinal medtech. Johnson & Johnson separately announced the acquisition of Firefly Bio for roughly $1 billion, expanding into KRAS-targeting degrader conjugates.